Indian Pharma Market sees 13 percent growth in September sales: AIOCD-AWACS Report

As per the report, IPM was valued at Rs. 176,841 Crore and the retail sector was valued at Rs 150,094 Crore as of MAT Sep'21. At the MAT level, IPM has grown by 18% & 17% at TSA and SSA, respectively.

Cardiac, anti-infective, gastrointestinal, anti-diabetic, Vitamins Minerals & Nutrients, respiratory, pain and derma therapies are among the top therapy trends for the month of September 2021, according to the survey.

Furthermore, the research claimed that in cardiac, Metoprolol plus Telmisartan grew at a rate of 15% while in anti-infective, Cefpodoxime Solids grew at a rate of more than 38%. In addition, in GI therapy, the Pantopr plus Domperid subgroup recorded the highest sales of 117 Crore.

Food supplements are the most profitable segment in Vitamins, Minerals, and Nutrients (VMN) therapy, accounting for 168 billion dollars in sales.

Cold prep, levosalbutamol comb, and Chlorphen+dextro prep all increased by triple digits for the month, while Paracetamol oral solids & liq. contributed 161 Crores of sales to the pain market, representing 39 percent and 128 percent growth, respectively.

Itraconazole achieved the biggest sales in the derma market, while emollients plus protectives grew by 16 percent to 93 crores, and other hair care preps grew by 28 percent.

In neuro therapy, Levetiracetam is the top valued subgroup with 75 crores of sales and 5% growth, while Gabapentin plus Nortriptylin showed the highest growth of 33%.

Conv Iron solids, Liquids, and Inj. have contributed a total of 278 crores to Gynaec therapy sales. Dydrogesteron and Human Menopausal Gonadotropin have the fastest growth, with 47 and 36 percent rise, respectively.

Sun Pharmaceutical Industries has maintained its lead in the Indian pharma market growth, with a market share of 7.23 percent, while Abbott has secured the second spot with a market share of 6.17 percent, and Cipla has remained in the third spot with a market share of 5.19 percent.

According to the analysis, Abbott, Cipla, Alkem, Macleods, Lupin, and Aristo all showed improvement in MS in September of this year compared to August of this year. Macleods has the largest growth in MS in September 21, compared to August. Intas, Sun, Mankind, and Torrent, on the other hand, show a drop in MS in Sep'21 compared to Aug'21.

In addition, Zydus, Emcure, Glenmark, and Micro all saw an increase in market share (MS) in September 21 compared to August 21. On September 21, DRL, GSK, IPCA, Sanofi, Pfizer, and USV reported lower Market Share (MS) than on August 21. MS has improved in September 21 compared to August 21 for Alembic, FDC, ERIS, Indoco, and Blue Cross. On September 21, MS for Franco, Cadila, Novartis, and Ajanta fell compared to August 21. Since August of this year, Centaur, Boehringer, and Reliance have all improved in MS. MSD, Meyer, Janssen, and Raptakos all reported lower MS rates in September than in August.

Further, in accordance with the top brands for the month of September, Mixtard is the topmost brand with 71 crores of sales & MS of ~0.43% for the month. Among the top 10 brands, Calpol has shown the highest growth, followed by Monocef.

Among the Top 25 products as per Sep'21 Month (in comparison to Aug'21 Month)

• Mixtard has maintained the No 1 position at month level as well

• Amongst the top 10 brands, Monocef growth was at 35% while Calpol grew at 79%

• Calpol, Dolo, Thyronorm & Novomix gained 1 ranks each to secure 4th ,12th ,13th & 14th position, respectively

• Clavam gained 2 rank each to secure 7th position with 27% growth

• Azithral gained 4 ranks to secure 8th position with 12% growth

• Influvac gained 15 ranks to secure 16th position with 63% growth

• Zifi gained 3 ranks to secure 20th position with 34% growth

• Duolin gained 6 ranks to secure 21st position with 44% growth

• Budecort gained 29 ranks to secure 22nd position with 53% growth

• Mikacin gained 9 ranks to secure 24th position with 14% growth

Also Read: Indian Pharma Sees Robust Growth Of 51.5 Percent In April Sales: AIOCD-AWACS Report